Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics
Open Access
- 4 January 1998
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 45 (1) , 49-55
- https://doi.org/10.1046/j.1365-2125.1998.00636.x
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophyPublished by Elsevier ,2003
- Pharmacological pleiotropism of the human recombinant α1A‐adrenoceptor: implications for α1‐adrenoceptor classificationBritish Journal of Pharmacology, 1997
- The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic HyperplasiaNew England Journal of Medicine, 1996
- Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned α1‐adrenoceptor subtypes and in human prostateJournal of Autonomic Pharmacology, 1996
- The hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasiaUrology, 1996
- Metabolism of tamsulosin in rat and dogXenobiotica, 1996
- Absorption, metabolism and excretion of tamsulosin hydrochloride in manXenobiotica, 1996
- Benign Prostatic Hyperplasia — Medical and Minimally Invasive Treatment OptionsNew England Journal of Medicine, 1995
- Cloning, Expression and Characterization of Human α Adrenergic Receptors α1a, α1b and α1cBiochemical and Biophysical Research Communications, 1994
- Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study GroupArchives of Family Medicine, 1993